Peaks from CD34+/monocyte-derived brain myeloid cells showed preferential enrichment for risk loci associated with multiple sclerosis, Alzheimer’s disease, intellectual disability, and depression in comparison to iHPCs peaks (Fig. 5l). The gene discussed is CD34; the disease is multiple sclerosis.